We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
NIH Friday confirmed preliminary remdesivir trial data showing that the drug delivered a median recovery time of 11 days compared with 15 on placebo, establishing it as the standard of care for patients with moderate to severe disease. Read More
A leading COVID-19 vaccine candidate has shown promise as being safe and effective in humans and produced an immune response against the coronavirus, according to preliminary data from a phase 1 trial of 108 healthy adults in China. Read More
Enrollment for a large, global trial of chloroquine and hydroxychloroquine for the prevention of COVID-19 is getting under way in the United Kingdom. Read More
AstraZeneca has nabbed an HHS contract worth up to $1.2 billion to speed development and production of the University of Oxford’s promising COVID-19 vaccine candidate. The deal also would lock in the distribution of 300 million doses of the vaccine for the U.S. Read More
Covis Pharma has begun a phase 3 trial of its approved asthma drug Alvesco (ciclesonide) in non-hospitalized COVID-19 patients ages 12 years and older. Read More